- Merck (MRK -0.2%) and Dynavax (DVAX -1%) enter into two clinical trial collaboration agreements to investigate the potential benefits of combining immunotherapies in the treatment of cancer. One collaboration will assess the combination of Merck's Keytruda (pembrolizumab) and Dynavax's toll-like receptor agonist, SD-101 and the other, Merck's investigational anti-interleukin-10 immunomodulator, MK-1966 with SD-101.
-
Interleukin-10 is an anti-inflammatory cytokine.
- A Phase 1b/2 trial evaluating the Keytruda combo in advanced melanoma will commence in H2. A Phase 1 study assessing the MK-1966 combo in solid or hematological malignancies will also commence in H2.
- Under the terms of the agreement, Dynavax will sponsor and fund the Keytruda study and Merck will sponsor and fund the MK-1966 study. The contracts include provisions to extend the collaboration into Phase 3 development. Additional details are not disclosed.
- This partnership is another example of the prevailing opinion in the oncology community that combining therapies with different mechanisms of action offers the best chance of success in fighting many cancers.